Use of PMCA for Biochemical Diagnosis of Prion Diseases Claudio Soto, PhD Dept of Neurology, University of Texas Medical Branch and Amprion Inc.

Slides:



Advertisements
Similar presentations
Distinctive characteristics
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Prion Disease Transmissible spongiform encephalopathy (TSE)
Removal of Prions by Plasma Fractionation Processes
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
PRION DISEASES BLOOD INFECTIVITY ISSUES Richard Knight NCJDSU.
CJD Overview Bob Will, National CJD Surveillance Unit, Edinburgh, UK Associazione Italiana Encefalopatie da Prion Milano 3 Ottobre 2009.
Metabonomics A New Potential Diagnostic Tool David Huffman Western Michigan University WDA 2010.
Prions Fact or Science Fiction?. Stanley Prusiner, 1982 Born in Des Moines, Ia. Suggested that spongiform encephalopathies in animals and humans are caused.
Prions Alicia Arguelles, Jerry Wang May 4, What are prions? proteinaceous infectious particle an infectious agent made only of protein, containing.
Mad Cow Disease. Effects of Mad Cow disease Mad cow disease, or bovine spongiform encephalopathy (BSE), is a fatal brain disorder that occurs in cattle.
PRION DISEASE & PENTOSAN POLYSULPHATE IN THE UK Richard Knight NCJDSU University of Edinburgh Scotland.
Holly Allen CREUTZFELDT-JAKOB DISEASE.  Human equivalent of mad cow disease  Rare, degenerative, fatal disease  Approximately 1 case per million per.
TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical.
Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD.
Chronic Subclinical Transmissible Spongiform Encephalopathy Infections.
1 Evaluation of Prion Reduction Filters with a Highly Sensitive Cell Culture-Based Infectivity Assay Evaluation of Prion Reduction Filters with a Highly.
Α-synuclein, Lewy Bodies, Prions, and Parkinson’s Disease Cody McCullough & Sara Homsi BCM 465 April 19 th, 2010.
Prions: Proteins Gone Bad
By : Amirah nu’aimi Sharifah Nurul Hanim TASK 2 – DISCUSS THE EXAMPLE OF PROTEIN FOLDING DISEASE BY STATING THE MECHANISM.
Founders With the support of Results4th Call for Projects NeuroPrion2010 Salzburg.
Creutzfeldt-Jakob’s disease or Prion Disease or Mad Cow disease It belongs to a group of neurodegenerative diseases called Transmissible Spongiform Encephalopathy.
PRIONS Kalina Estrada TA: Yu-Chen Hwang Thursday, 7-8pm.
1 HPerron TSEAC Detection of PrP res in plasma H. Perron Presented by P van Driessche.
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
Proposed algorithm for approval of human TSE tests in Europe.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.
Prion Digestion in the Alimentary Tract Nicholas Toney.
12 August 2003 CJD Update Latest facts, figures & findings Jonathan P Clewley TSE Unit, Virus Reference Division, Centre for Infections 20 May 2005.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.
John Gray, Sandor Dudas and Stefanie Czub
Taylor Goldbeck.  Professor and Head of Neuropathology at Yale- Department of Surgery and Faculty of Neurosciences and Virology  Focuses on dementia.
WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies World Health Organization 2006 Proceedings of a Consultation.
TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
Prion cell tropism significantly varies among animal species, depending on both the agent strain and host-specific factors. For example, prions show high.
C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.
Proteins as Pathogens Stanley B. Prusiner, MD The Nobel Prize in Physiology or Medicine Presented by Shannon S. Rickner-Schmidt.
TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
PRIONS 221.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Founders With the support of. 2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual.
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
The History of Chronic Wasting Disease Dr. Trent Bollinger, CCWHC One World, One Health Symposium Sept. 29, 2004.
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.
Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.
VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
Aya Murakami. Background Transmissible Spongiform Encephalopathies and Prion Other for TSEs CWD Distribution in the US Symptoms and Diagnosis Biomarkers.
Today’s Lecture: Bringing the disease to YOU! From the 1950s to NOW From Papua New Guinea to the U.S.A.
+ High CJD infectivity remains after the prion protein is destroyed By Sylvester Gates.
(Bovine spongiform encephalopathy)
Disease Transmission and Species Barrier
Rabies virus and Prion Dongli Pan
KEY CONCEPT Infections can be caused in several ways.
In Vitro Generation of Infectious Scrapie Prions
Nat. Rev. Neurol. doi: /nrneurol
Fig. 4. Prion infectivity of skin samples from sCJD patients.
Nat. Rev. Neurol. doi: /nrneurol
Grass Plants Bind, Retain, Uptake, and Transport Infectious Prions
Volume 134, Issue 5, Pages (September 2008)
De novo generation of cervid prions.
Fluconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.
Transmissible Proteins: Expanding the Prion Heresy
Western blot analysis of skin tissue from CJD and non-CJD patients
Presentation transcript:

Use of PMCA for Biochemical Diagnosis of Prion Diseases Claudio Soto, PhD Dept of Neurology, University of Texas Medical Branch and Amprion Inc.

Importance of Prion Diagnosis Food industry Blood banks Plasma products Disease diagnosis Clinical trials Brain surgery Drugs from human origin Organ transplant Soto (2005) Nature Rev Microbiol. 2:

PrP sc Is the most specific marker for the disease. However, its levels in body fluids and tissues other than nervous system are too low to be detected Design a more sensitive test for PrP sc detection or Amplify the level of the marker (PrP Sc ) The problem of Prion Diagnosis

d y Clinical symptoms y PrP C Slow process PrP Sc Infection Incubation Time Disease PrP Sc amplification during disease propagation

PrP C Incubation Growing of units Incubation Growing of units + Protein Misfolding Cyclic Amplification (PMCA) PrP Sc Soto et al. (2002) Trends Neurosci. 25: Sonication Multiplication of units Sonication Multiplication of units

Brain homogenates Healthy hamster Sick hamster (263k) PK digestion WB analysis Amplification (Incubation + sonication) PMCA: Proof of concept source of PrP Sc source of PrP c PrP res fragment PK + + PMCA - + Saborio, Permanne and Soto (2001) Nature 411:

One-by-one 96 format control Amplified Non Amplified Automated PMCA

Ultrasensitive detection of PrP Sc by serial PMCA 1.0x10 3 Dilution Non amplified Amplification factor ~ 6600 fold 3.0x x x x x x x x10 6 NBH -PK 2.0x x PMCA cycles 1:10 1 st PMCA (96 cycles) 2 nd PMCA (118 cycles) 2.5x10 4 Dilution 1.3x x x10 6 Dilution 3.1x x x x x x x x x10 3 NBH -PK NBH -PK 2.5x x10 12 Non amplified Amplification factor ~10 million folds Castilla, Saa and Soto (2005) Nature Medicine 11:

NBH -PK Scrapie LD50 spiked 1 st PMCA (144 cycles) 2 nd PMCA (144 cycles) 3 rd PMCA (144 cycles) 4 th PMCA (144 cycles) Non amplified What is the minimum quantity detected? 4 th PMCA (144 cycles) Scrapie LD50 spiked 7 th PMCA Our mathematical estimation is that LD50 contains around molecules of PrP monomer Saa, Castilla, and Soto (2006) J. Biol. Chem (In press)

Sensitivity of PrP Sc detection by different methods 7 rounds PMCA 1.0 x ag 26 3,300,000,000 1 round PMCA 2 rounds PMCA Saa, Castilla, and Soto (2006) J. Biol. Chem (In press)

Symptomatic phase Plasma0.1 pg/ml = 2 x 10 7 molecules Buffy coat1 pg/ml = 2 x 10 8 molecules Incubation period (pre-symptomatic phase) Plasma pg/ml = 1-2 x 10 6 molecules Buffy coat pg/ml = 1-2 x 10 7 molecules Can we detect PrP Sc in blood? How much PrPSc is there in blood? Our sensitivity Single PMCA: 65 pg/ml = 1.3 x 10 9 molecules/ml Double PMCA: 0.02 pg/ml = 4 x 10 5 molecules/ml 7 th rounds PMCA: fg/ml = 500 molecules/ml Taken from Brown et al (2001) J. Lab Clin. Invest. 137: 5-13 In other words sensitivity of PrP Sc detection as compared with standard western blot has to be increase by 100,000 – 1,000,000 fold

Can we detect PrP Sc in blood? Castilla, Saa and Soto (2005) Nature Medicine 11:

Pre-symptomatic detection of PrP Sc in blood Blood taken during incubation period Infection Clinical disease 14 days I1 C1 I2 C2 I3 C3 I4 C4 I5 C5 NBH -PK /5 20 days40 days60 days70 days80 daysSymptomatic 3/6 I1 I2 I3 I4 I5 I6 C1 C2 C3 C4 NBH -PK /10 I1 I2 I3 I4 I5 I6 I7 I8 I9 I10 C1 C2 C3 C4 C5 NBH -PK /5 I1 I2 I3 I4 I5 C1 C2 C3 C4 NBH -PK /5 C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 NBH -PK /5 C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 NBH -PK /10 C1 I1 C2 I2 C3 I3 C4 I4 C5 I5 C6 I6 C7 I7 C8 I8 C9 I9 C10 I10 NBH -PK Saa, Castilla and Soto (2006) Science 313:92-94

Leakage from the brain? Peripheral prion replication? Symptomatic phase Pre-symptomatic detection of PrP Sc in blood Saa, Castilla and Soto (2006) Science 313:92-94

Application of PMCA to different samples sCJD type 1 sCJD type 2 vCJD

What is next? Adapt and optimize blood detection of PrP Sc in relevant natural samples (cow, human, sheep, deer) Large scale study to evaluate the detection of PrP Sc in blood of healthy donors in countries with high risk of vCJD (UK, France, etc) Study earliest time in which PrP Sc can be detected in humans (primate model, familial cases) and in cattle (experimental infection model) Optimize the method for detection in other blood components (plasma, red cells) and other biological fluids (urine, CSF). Develop the technology into a high throughput and practical test

Joaquín Castilla, PhD Rodrigo Morales Paula Saá June Yowtak Lisbell Estrada Jorge de Castro Becky Daniels Claudio Soto, PhD Karim Abid, PhD

Gabriela Saborio, MD Celine Adessi, PhD Kinsey Maundrell, PhD Bruno Permanne, PhD Youcef Fezoui, PhD Raphaele Buser, PhD Milene Russelaskis, PhD Claudio Hetz, PhD Sergio Benavent Laurence Anderes Marie-Jose Frossard Santiago Fraga Elizabeth Vial Sergio Peano, MD Thomas Ruckle, PhD Former lab members Case Western Reserve University Pierluigi Gambetti CJD Unit, Edinburgh, UK Robert Will James Ironside Istituto Carlo Besta, Italy Fabrizio Tagliavini US Department of Agriculture Juergen Richt Istituto Superiore di Sanita, Italy Maurizio Pocchiari University of Kentucky Glenn Telling University of Edinburgh, UK Jean Manson University of Zurich, Switzerland Adriano Aguzzi Mathias Heikenwalder Collaborators